Quality of life effects of renal artery stenting versus medical therapy for atherosclerotic renal-artery stenosis: results from the randomized CORAL trial
Authors' conclusion
In a large, multicenter, randomized clinical trial, we found no significant benefit of routine renal-artery stenting over medical management for the treatment of atherosclerotic renal-artery stenosis in terms of disease-specific or generic quality of life measures.
Study context
- Population
- Patients with atherosclerotic renal-artery stenosis (mean age 69.2 ± 9.1 years, 49.7% men)
- Participants
- 906 patients
- Comparison
- Renal-artery stenting vs medical therapy
- Primary endpoint
- Quality of life over time: Physical Symptoms Distress Index (PSDI), SF-36 and EQ-5D scores
Methodological detailspre-specified quality of life sub-study, multicentre, open-label
- Pre-specified quality of life sub-study
- Multicentre
- Open-label
Primary result
As reported in the abstract
Quality of life (PSDI, SF-36, EQ-5D)
- Symptom frequency and distress from antihypertensive side effects (Physical Symptoms Distress Index (PSDI)) changed minimally over time, no significant differences between groups
- No clinically significant differences between groups for SF-36 and its subscales or EQ-5D
Secondary outcomes
Internal validation of quality of life measures
- PSDI correlated well with number/type of antihypertensive medications
- Generic health status measures correlated with late clinical events
Original publication
Quality of life effects of renal artery stenting versus medical therapy for atherosclerotic renal-artery stenosis: results from the randomized CORAL trial. Eur Heart J Qual Care Clin Outcomes. Published 14 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →